Bruna Rocha represents pharmaceutical companies, clinical research organizations, biotechs, digital health providers and cannabis companies in transactional and regulatory matters. She works alongside C-level executives, investors, developers, managers and physicians in every aspect of their legal activities, advising on matters ranging from business formation and the establishment of investment platforms for companies moving into new markets, to cross-border portfolio acquisitions and restructuring.

Bruna additionally advises companies on medical therapies at every stage of the laboratory-to-market process. Within this space, she counsels on intellectual property; regulatory and reputational risks arising from product liability and product safety concerns; and tech innovation, including the use of artificial intelligence in the healthcare space, mobile medical applications, health information exchange, the Internet of Medical Things (IoMT), wearable devices and bio printing, among others.

 

DLA Piper and Campos Mello Advogados (CMA) are separate and independent law firms, which work in cooperation with one another. Partners of DLA Piper are not partners of CMA; and CMA partners are not partners of DLA Piper.